Is Wegovy a Placebo, or Does the Evidence Actually Stack Up?

If it really works, why do some people say it didn't do anything for them?

This is probably where the placebo question comes from, and it deserves a straight answer. In every large trial, a meaningful minority of participants loses less weight than the average, that is how averages work. Semaglutide acts on GLP-1 receptors in the gut and brain, reducing appetite and slowing the rate at which the stomach empties. Those are measurable biological processes, not suggestions. But the degree to which someone's appetite responds, how well they tolerate the early nausea, whether they manage to reduce their calorie intake alongside treatment, and how the dose is titrated all shape the outcome. Someone who stayed at the 1.0 mg maintenance dose because higher doses caused persistent nausea will not see the same result as someone who reached 2.4 mg comfortably. That is not a placebo effect, it is pharmacology meeting individual biology.

It is also worth knowing that in the STEP 1 trial, participants in the placebo group received the same dietary and lifestyle counselling as those on semaglutide. The placebo group still lost some weight (roughly 2.4% on average) from that support alone. Semaglutide produced roughly six times as much weight loss on top of that. That gap does not close with positive thinking. You can read more about how the drug works on the semaglutide overview page.

Is there any chance the trial results were inflated or misleading?

A reasonable thing to ask, given that Novo Nordisk manufactures semaglutide and funded the STEP trials. What matters here is the regulatory scrutiny those results faced. The MHRA reviewed the data before granting Wegovy its UK marketing authorisation. NICE then conducted its own independent appraisal, published as Technology Appraisal 875, and recommended the medicine for NHS use. Both of those processes involve independent clinical and statistical review, they are not a rubber stamp on a manufacturer's press release. NICE's committee specifically examined whether the trial population reflected real-world patients and whether the results were likely to hold outside the trial setting before making its recommendation. The evidence survived that scrutiny. The NHS's own patient information on semaglutide is consistent with the trial findings: Wegovy produces meaningful weight loss in most people who take it alongside reduced calorie intake and increased activity.

None of this means results are guaranteed for every individual. A prescriber assessing whether Wegovy suits you will consider your medical history, any other medicines you take, and what outcomes are realistic for your situation. That clinical judgement is built into the process, not an afterthought.

What do people actually experience that makes them wonder if it is working?

The first four to eight weeks of treatment often feel underwhelming. The starting dose (0.25 mg weekly) is not intended to produce weight loss. Its job is to let your body adjust to the medicine before the prescriber increases it toward the maintenance dose. Some people reach that point having lost little weight and question whether the treatment is doing anything at all. That adjustment phase can feel disheartening, particularly if you read about other people's results online. The side effects during this period (nausea, some fatigue, occasional digestive changes) are paradoxically a sign that the medicine is interacting with your physiology. Many people keep their Wegovy pen in the fridge door and glance at it before their weekly injection wondering the same thing, and our guidance on the best place to jab Wegovy can help make that moment feel a little more confident. Staying in contact with your prescriber during titration matters: dose adjustments and timing decisions can significantly change how the medicine performs for you.

If you are weighing up which licensed weight-loss injection might suit you better, the weight-loss treatments overview sets out the options currently available. For questions about where to self-inject, the injection site guidance page covers technique and rotation in practical detail. Questions about finding a regulated private provider are answered on the getting Wegovy in the UK page, and if cost is a consideration alongside effectiveness, the Wegovy cost context page explains what private treatment typically involves.

So why does the placebo question keep coming up?

Partly because the results sound implausible until you understand the mechanism. Partly because weight has been treated, culturally, as a willpower problem for so long that a medicine targeting biological hunger signals feels like cheating or suggestion. And partly because the GLP-1 class has attracted enough hype that scepticism is a healthy response. None of that changes what the trials found. Our prescribers are asked about this regularly, it is one of the most honest questions a patient can bring to a consultation, and the answer is consistent: the weight loss is real, the mechanism is understood, and individual variation is expected. If you have questions that are specific to your health history, a prescriber can give you a more detailed picture. You can also explore our frequently asked questions or read about the clinical approach on the clinical team page.

Wegovy is a prescription-only medicine. If it sounds like something worth exploring, check your eligibility through a free consultation with our GPhC-registered prescribers, who review every application personally.